- “AP” Rated and therapeutically equivalent to Carnitor®*1
- Vial closure is not made with natural rubber latex
|Pack NDC#||Strength||Supplied As||Shelf Pack||Vial Opening Size||Product Info||Availability|
*All trademarks are the property of their respective owners.
1. Orange book: Approved drug products with therapeutic equivalence evaluations. U.S. Food & Drug Administration.https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=A&Appl_No=075861#24057
Accessed January 19, 2023.
(8:00am–6pm Monday - Thursday and Friday 8:00am–4pm Eastern Time)
F: 610-650-0170E: firstname.lastname@example.org
Adverse Drug Events (ADEs) may be reported to the FDA:
P: 888-354-4859E: email@example.com
(9am–5pm Eastern Time, Monday - Friday)E: firstname.lastname@example.org
For drug information outside of normal business hours that cannot wait until the next day, please call:
American Regent, Inc.
5 Ramsey Road
Shirley, NY 11967
FOR INTRAVENOUS USE ONLY
INDICATIONS AND USAGE
For the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency.
For the prevention and treatment of carnitine deficiency in patients with end-stage renal disease who are undergoing dialysis.
IMPORTANT SAFETY INFORMATION
Serious hypersensitivity reactions, including anaphylaxis, laryngeal edema, and bronchospasm have been reported following levocarnitine administration, mostly in patients with end-stage renal disease who are undergoing dialysis. Some reactions occurred within minutes after intravenous administration of levocarnitine.
If a severe hypersensitivity reaction occurs, discontinue levocarnitine treatment and initiate appropriate medical treatment. Consider the risks and benefits of re-administering levocarnitine to individual patients following a severe reaction. If the decision is made to re-administer the product, monitor patients for a reoccurrence of signs and symptoms of a severe hypersensitivity reaction.
The safety and efficacy of oral levocarnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine and trimethylamine-N-oxide, since these metabolites are normally excreted in the urine.
Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments.
There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed.
Levocarnitine supplementation in nursing mothers has not been specifically studied. Studies in dairy cows indicate that the concentration of levocarnitine in milk is increased following exogenous administration of levocarnitine. In nursing mothers receiving levocarnitine, any risks to the child of excess carnitine intake need to be weighed against the benefits of levocarnitine supplementation to the mother. Consideration may be given to discontinuation of nursing or of levocarnitine treatment.
Clinical Trials Experience
Transient nausea and vomiting have been observed. Less frequent adverse reactions are body odor, nausea, and gastritis.
The following adverse reactions have been reported:
Neurologic Reactions: Seizures have been reported to occur in patients, with or without pre-existing seizure activity, receiving either oral or intravenous levocarnitine. In patients with pre-existing seizure activity, an increase in seizure frequency and/or severity has been reported.
Hypersensitivity reactions: Anaphylaxis, laryngeal edema, and bronchospasm.
For additional safety information, please see Full Prescribing Information.
You are encouraged to report adverse drug events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.